Compare Delta Air Lines, Inc. (DAL) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Delta Air Lines, Inc. vs Ginkgo Bioworks Holdings Inc — how do they compare? Delta Air Lines, Inc. trades at $80.67 (market cap $54.02B), while Ginkgo Bioworks Holdings Inc trades at $12.65 (market cap $763.64M). The key difference: Delta Air Lines, Inc. is far larger — about 70.7× Ginkgo Bioworks Holdings Inc's market cap, and Delta Air Lines, Inc. pays a 1.05% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Delta Air Lines, Inc. for 97 Days and Ginkgo Bioworks Holdings Inc for 7 Days on average.
| DAL | DNA | |
|---|---|---|
Market Cap | $54.02B | $763.64M |
Volume | 9,632,845 | 3,204,177 |
Sector | Industrials | Health |
52-Week High | $93.66 | $15.83 |
52-Week Low | $55.65 | $5.48 |
Typical Hold Time | 97 Days | 7 Days |
Enterprise Value | $69.34B | $865.59M |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Delta Air Lines (DAL) trades at $82.97, down 0.82% on the day, with a bearish technical signal despite strong fundamentals. The company has beaten earnings estimates for three consecutive quarters and maintains solid profitability with 5.78% net margin and 20.12% ROE. Recent news highlights competitive pressures from United and American Airlines' customer poaching efforts and Elon Musk's criticism over Delta's Wi-Fi provider choice.
DAL presents a compelling value opportunity with a P/E of 13.62 below industry averages and strong analyst consensus (82% buy ratings) targeting $103.36. However, rising fuel costs, competitive threats to premium customers, and bearish technical indicators create near-term headwinds. The upcoming Q3 earnings report on October 9 will be crucial for validating the company's margin resilience.
Ginkgo Bioworks (DNA) trades at $12.84, up 11.94% in the last session. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million in 2025 on $170.16 million revenue, with a negative net margin of 219.6%. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting strategic growth initiatives despite financial challenges.
Outlook remains speculative with high risk. The buy/hold/sell analyst split is nearly even, reflecting uncertainty. Significant cash burn and persistent losses pose substantial risks, but partnerships and government contracts offer potential catalysts. Investors should weigh the company's long-term biotechnology prospects against its current lack of profitability and negative cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
